Alliance Pharma (Ampersand-backed) Acquires LGC's Drug Development Solutions; KKR Joins as Equal Shareholder

Ampersand Capital Partners Invests in Alliance Pharma

November 18, 2021

Healthcare Services

Ampersand Capital Partners has made a growth equity investment in Alliance Pharma, a Malvern, Pennsylvania–based bioanalytical CRO. The funding will support Alliance’s expansion of global reach, scientific capabilities, and operational capacity while founder Frank Li remains a significant shareholder.

Astorg and Cinven Acquire LGC

November 21, 2019

Healthcare Services

A consortium led by private equity firms Astorg and Cinven has signed an agreement to acquire LGC, a UK-headquartered global leader in life sciences tools. The buyout will back LGC’s continued organic growth and M&A-led expansion across its standards, genomics and laboratory services businesses; financial terms were not disclosed and the transaction remains subject to regulatory approvals.

GHO Capital and Partners Group Invest in Sterling Pharma Solutions

May 25, 2023

Pharmaceuticals

GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.

GHO Capital Acquires Majority Stake in Sterling Pharma Solutions

February 28, 2019

Pharmaceuticals

GHO Capital has acquired a majority stake in Sterling Pharma Solutions alongside management. The investment will support Sterling's international expansion and accelerate growth of its specialist API development and GMP manufacturing capabilities from its UK base in Newcastle upon Tyne.

Ampersand Capital Partners Recapitalizes American Laboratory Products Company (ALPCO)

September 21, 2020

Medical Devices

Ampersand Capital Partners completed a majority recapitalization of American Laboratory Products Company (ALPCO) to provide growth capital for expanding ALPCO's diagnostics test kit offering, geographic reach, and R&D/production capabilities. Founders Richard and Jan Conley will remain shareholders, Sean Conley will continue as CEO, and Larry McCarthy, PhD was named Board Chairman.

Ampersand Capital Partners Majority Recapitalizes Phosphorex

August 25, 2022

Healthcare Services

Ampersand Capital Partners completed a majority recapitalization of Phosphorex to provide growth capital enabling the company to build out a 30,000 sq. ft. facility and establish cGMP manufacturing capabilities for lipid nanoparticles, microspheres and other drug-delivery platforms. The investment positions Phosphorex to expand from development and analytical services into end-to-end CDMO manufacturing to better serve pharmaceutical and biotechnology clients.